Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Danish study finds link between community C diff, proton pump inhibitors
Originally published by CIDRAP News Feb 25
A nationwide study in Denmark found an association between the use of proton pump inhibitors (PPIs) and increased risk of community-associated Clostridioides difficile infections (CA-CDI), Danish researcher reported today in Clinical Infectious Diseases.
For the study, researchers from Denmark's Statens Serum Institute used the Danish National Microbiological Database to identify all incident episodes of CA-CDI in Danish adults from February 2010 through December 2013. They obtained data on filled prescriptions for PPIs, which neutralize or reduce the production of gastric acid, from the Danish National Prescription Registry.
The researchers conducted self-controlled case-series analyses to estimate incidence-rate ratios (IRRs) for CA-CDI, comparing periods with and without exposure to PPIs, and adjusted their models to account for confounders such as chronic disease, genetics, hospital stays, and antibiotic and corticosteroid use.
Of the 3,583 CA-CDI episodes identified, 964 occurred during current use of PPIs, 324 occurred 0 to 6 months after treatment cessation, 123 occurred 6 to 12 months after treatment cessation, and 2,172 occurred during periods with no use of PPIs. When the investigators compared the incidence of CA-CDI during current use of PPIs with periods of non-use, the unadjusted IRR was 2.78 (95% confidence interval [CI], 2.40 to 3.22). When adjusted for hospitalization, antibiotic use, and corticosteroid use, the IRR was 2.03 (95% CI, 1.74 to 2.36). The increased risk remained elevated for extended periods: 1.54 (95% CI, 1.31 to 1.80) for 0 to 6 months and 1.24 (95% CI, 1.00 to 1.53) for 6 to 12 months.
The study authors note that while previous observational studies have found varying levels of association between PPI use and CDI, the association has been questioned because of the absence of data from randomized controlled trials and insufficient adjustment for confounding factors.
"This large study with thorough control for confounding significantly adds to the body of evidence that increased risk of CDI, even in the community setting, should be considered when prescribing CDIs, although the underlying biological mechanisms need to be explored," they write.
Feb 25 Clin Infect Dis study
Report examines social science insights on antibiotic use
Originally published by CIDRAP News Feb 25
The London School of Hygiene and Tropical Medicine (LSHTM) yesterday released a new report on antibiotic use in low- and middle-income countries (LMICs) that focuses on social science research and the emerging insights on novel ways to address antimicrobial resistance (AMR).
The report from LHSTM's Fresh Approaches to the Study of Antimicrobials in Society project examines antibiotic use in LMICs through three different lenses: practices, structures, and networks. The idea behind the report, which combines insights gleaned from a growing body of published social science research into AMR and from a series of panel discussions held in 2020, is to formulate ideas of how these insights can be used to develop local interventions for addressing human and animal antibiotic use in a diverse range of settings.
Among the key themes identified in the report is that antibiotic use in many LMICs does not primarily result from a lack of knowledge about AMR but is related to a web of social, economic, political, and historic conditions, and that modifying how people in these countries use antibiotics requires addressing these issues. Another theme is that fractured healthcare systems and lack of access to clean water and sanitation infrastructure have become structural drivers of antibiotic use in many countries, and fixing these structures, rather than focusing on individual antibiotic use, could lead to longer-term solutions.
"In the last few years, there has been a growing acknowledgement of the vital role of social science in understanding and intervening on antibiotic use, a key driver of AMR," author Clare Chandler, PhD, MSc, director of the LSHTM Antimicrobial Resistance Centre, writes in the report. "The growing concern that our off-the-shelf toolkit for addressing antibiotic use is insufficient in the face of rising use across humans, animals and plants, requires that we take a fresh look at the ways we are understanding this problem and possibilities for solutions."
Feb 24 LSHTM report
CARB-X to fund development of drug to rejuvenate ineffective antibiotics
Originally published by CIDRAP News Feb 23
CARB-X announced today that it is awarding up to $2.2 million to the University of Queensland's Institute for Molecular Bioscience (IMB) to continue developing new compounds designed to boost antibiotics that have become ineffective against drug-resistant bacterial infections.
The award will help fund IMB's octapeptins research program, which is developing octapeptin peptides that can disrupt the protective outer cell membrane of drug-resistant gram-negative bacteria, allowing antibiotics that have lost efficacy to work again. IMB researchers are currently trying to identify which antibiotics octapeptins are best at helping and can be combined with.
"We will harness this latest funding injection to investigate which existing antibiotics can be rejuvenated by combining them with compounds from the octapeptin family," Mark Blaskovich, PhD, director of the IMB Centre for Superbug Solutions, said in a CARB-X (the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) press release.
Octapeptins are being designed for use in low- and middle-income countries, where there are high levels of drug-resistant bacteria and many cheap, generic antibiotics have lost efficacy.
This is the second round of funding IMB has received from CARB-X for the Octapeptins project.
Feb 23 CARB-X press release
WHO details initial Global Leaders Group meeting
Originally published by CIDRAP News Feb 23
The World Health Organization (WHO) today released a report on the inaugural meeting of the One Health Global Leaders Group (GLG) on Antimicrobial Resistance (AMR).
The group, which is co-chaired by Bangladesh Prime Minister Sheikh Hasina Wazed and Barbados Prime Minister Mia Mottley and includes other heads of state, researchers, and key stakeholders, met Jan 26 and 27 to share ideas and discuss visions for their mission. It was the GLG's first meeting since being launched in November 2020 to provide political leadership for global, regional, and national efforts to address AMR and its impact on humans, animals, and the environment.
According to the WHO report, the members agreed that all GLG actions should add value to the global AMR response and should be guided by evidence and accountability, that national AMR action plans should by the bedrock of the global AMR response, and that there is a need to bolster popular and political support for efforts to tackle AMR.
The group also discussed ideas for a draft action plan to achieve their objectives. Members agreed that the action plan should be ambitious and evidence-based, with a focus on deliverable actions, should focus on the root causes of AMR, and should prioritize efforts to ensure sustained and dedicated funding.
They concluded that the five categories of recommendations created by the Interagency Coordination Group on AMR (accelerating progress in countries; research and development and innovations to secure the future; enhancing civil society and private sector engagement; investments and sustainable financing; and strengthening global governance with accountability) should provide the overall structure for their action plan.
The GLG plans to meet four times a year.
Feb 23 WHO report
Australia releases One Health action plan for antimicrobial resistance
Originally published by CIDRAP News Feb 22
The Australian government late last week released a One Health Master Action Plan (OHMAP) to support the country's 2o20 AMR strategy.
The plan highlights areas the Australian government and other stakeholders need to focus on to achieve the seven objectives of the 202o AMR strategy, which established a 20-year vision to minimize the development and spread of AMR in humans, animals, and the environment. The objectives include clear governance for AMR initiatives, prevention and control of infections, greater public awareness of AMR, appropriate antibiotic use and stewardship practices, integrated surveillance, and a strong collaborative research agenda across all sectors.
To achieve these goals, the action plan calls for the creation of sustainable funding for AMR initiatives based on evidence of the economic and societal costs of drug-resistant infections, the adoption of evidence-based and nationally consistent standards for infection prevention and control, and the development of coordinated, evidence-based antibiotic prescribing guidelines across all sectors. It also calls for the creation of a One Health communication strategy, a national One Health surveillance system, and a national AMR research and development agenda.
"By implementing a One Health approach with the OHMAP guiding the way, Australia can minimise the development and spread of antimicrobial resistance and ensure the continued availability of effective antimicrobials," the plan states. "This will help achieve a healthier future for Australians."
Feb 19 Australia One Health Master Action Plan
Mar 13, 2020, Australia's National Antimicrobial Resistance Strategy
